| 000 | 01816 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517105634.0 | ||
| 264 | 0 | _c20170308 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1877-8755 | ||
| 024 | 7 |
_a10.1007/s13105-016-0506-4 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKurt, Asuman | |
| 245 | 0 | 0 |
_aThe effects of n-3 long-chain polyunsaturated fatty acid supplementation on AGEs and sRAGE in type 2 diabetes mellitus. _h[electronic resource] |
| 260 |
_bJournal of physiology and biochemistry _cDec 2016 |
||
| 300 |
_a679-687 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aArginine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aBlood Glucose _xmetabolism |
| 650 | 0 | 4 |
_aBlood Pressure _xdrug effects |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 2 _xblood |
| 650 | 0 | 4 | _aDietary Supplements |
| 650 | 0 | 4 | _aFasting |
| 650 | 0 | 4 |
_aFatty Acids, Omega-3 _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGene Expression Regulation |
| 650 | 0 | 4 |
_aGlycated Hemoglobin _xmetabolism |
| 650 | 0 | 4 |
_aGlycation End Products, Advanced _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aLysine _xanalogs & derivatives |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNF-kappa B _xblood |
| 650 | 0 | 4 |
_aReceptor for Advanced Glycation End Products _xblood |
| 650 | 0 | 4 | _aSignal Transduction |
| 650 | 0 | 4 |
_aWaist Circumference _xdrug effects |
| 700 | 1 | _aAndican, Gülnur | |
| 700 | 1 | _aSiva, Zeynep Oşar | |
| 700 | 1 | _aAndican, Ahat | |
| 700 | 1 | _aBurcak, Gülden | |
| 773 | 0 |
_tJournal of physiology and biochemistry _gvol. 72 _gno. 4 _gp. 679-687 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s13105-016-0506-4 _zAvailable from publisher's website |
| 999 |
_c26256203 _d26256203 |
||